臨床婦人科産科72巻6号

2018年06月発行

今月の臨床 がん免疫療法の新展開─「知らない」ではすまない今のトレンド

がん免疫療法の分類と作用機序

免疫チェックポイント阻害薬とは何か

著者： 濵西潤三¹ 万代昌紀¹

所属機関： ¹京都大学医学部附属病院産科婦人科

ページ範囲：P.530 - P.541

文献概要

●免疫チェックポイント阻害薬には，主にCTLA-4阻害薬とPD-1経路阻害薬がある．

●免疫チェックポイント阻害薬は，T細胞性免疫を活性化することにより，抗腫瘍作用を発揮する．

●免疫チェックポイント阻害薬には，免疫活性に伴う特有の副作用に注意が必要である．

参考文献

1）Keir ME, et al : PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 : 677─704, 2008

2）Hamanishi J, et al : Immune checkpoint inhibition in ovarian cancer. Int Immunol 28 : 339─348, 2016

3）Iwai Y, et al : Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci Apr 24 : 26, 2017

4）Hodi, et al : Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 : 711─723, 2010

5）Okazaki T, et al : PD-1 and PD-1 ligands : from discovery to clinical application. Int Immunol 19 : 813─824, 2007

6）濵西潤三，他 : 婦人科がんに対するがん免疫療法の新展開─PD-1経路阻害薬への期待．医学のあゆみ263 : 97─103，2017

7）Hamanishi J : PD-1 signal blockade for ovarian cancer : perspectives and issues. Ann Oncol 28（suppl 9）, 2017

8）Hamanishi J, et al : Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol Dec 33 : 4015─4022, 2015

9）Varga A, et al : Pembrolizumab in patients（pts） with PD-L1-positive（PD-L1+）advanced ovarian cancer : updated analysis of KEYNOTE-028. J Clin Oncol 35, 2017（suppl ; abstr 5513）

10）Spira A, et al : Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer : phase I/II ECHO-202 study. ASCO, 2017

11）Lee JM, et al : Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly（ADP-ribose）polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women's cancers : a dose-escalation, phase I study. J Clin Oncol 35 : 2193─2202, 2017

12）Ott PA, et al : Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer : results from the KEYNOTE-028 Study. J Clin Oncol 35 : 2535─2541, 2017

13）Mehnert JM, et al : Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 126 : 2334─2340, 2016

14）Paoluzzi L, et al : Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 6 : 24, 2016

15）Frenel JS, et al : Pembrolizumab in patients with advanced cervical squamous cell cancer : preliminary results from the phase Ib KEYNOTE-028 study. J Clin Oncol 34, 2016（suppl ; abstr 5515）

16）Hollebecque A, et al : An open-label, multicohort, phase 1/2 study of nivolumab in patients with virus-associated tumors（CheckMate 358） : efficacy and safety in recurrent or metastatic cervical. vagina, and vulvar cancers. J Clin Oncol 35, 2017（suppl ; abstr 5504）

17）Algazi AP, et al : Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122 : 3344─3353 2016

18）Hamanishi J, et al : Specific gene signatures and oligo-clonal expansion of B cell repertoire with responders of anti-PD-1 antibody（Nivolumab）for ovarian cancer : Novel predictive biomarkers. 2016 ASCO Annual Meeting. J Clin Oncol 34, 2016（suppl ; abstr 55131）